Situational and psycho-social factors associated with relapse following residential detoxification in a population of Irish opioid dependent patients

Size: px
Start display at page:

Download "Situational and psycho-social factors associated with relapse following residential detoxification in a population of Irish opioid dependent patients"

Transcription

1 O R I G I N A L PA P E R Situational and psycho-social factors associated with relapse following residential detoxification in a population of Irish opioid dependent patients Kevin Ducray, Catherine Darker, Bobby P Smyth Ir J Psych Med 2012; 29 (2): Abstract Aims: To identify and describe the context and factors involved in the opioid lapse process following discharge from an Irish inpatient opioid detoxification treatment programme. Design, participants, setting: Prospective follow-up study of consecutive detoxified opioid dependent patients treated in a specialist inpatient drug dependency unit. Measurements: The Maudsley Addiction Profile and a structured interview were administered to 109 patients, months after discharge. Findings: Of 109 people interviewed at follow-up, 102 (94%) reported at least one episode of opioid use after leaving the residential treatment programme. Eighty eight patients (86% of the lapsers) identified more than one major factor contributing to their recidivism. The median number of factors identified as having a major role in the lapse was four. The most frequently reported major contributors to lapse were low mood (62%), difficulties with craving (62%), ease of access to heroin (48%) and missing the support of the treatment centre (43%). Conclusions: Early lapse was common following inpatient treatment of opioid dependence. Lapse tended to result from a number of common, identifiable, high-risk situations, feelings and cognitions which may assist clinicians and patients develop lapse prevention strategies to anticipate and interrupt this process. Key Words: Lapse, relapse, opioids, heroin, relapse- prevention, psychological, drug, addiction, abstinence, social. 1. Background Over the past four decades the major misused opioid in Ireland has been heroin. 1 Methadone substitution treatment, a harmreduction strategy, is currently the dominant intervention for opioid dependence. 2 Despite the robust evidence that methadone maintenance treatment (MMT) reduces mortality, drug use and associated criminal behaviour, 3 there is increasing international pressure 4 to provide recovery orientated treatments which may include medically supported opioid detoxification. Detoxification is the general term referring to the structured process whereby patients aspiring to live drug free lives are medically weaned from either illicit or prescribed opioids. Opioid detoxification completion is higher where treatment is residential or inpatient. 5-7 Irish national treatment protocols for opioid dependence have recently undergone a major external review 8 resulting in an increased accent on opioid detoxification 9 as a treatment goal for this typically chronic and relapsing condition. 10 The 2009 Irish Comptroller and Auditor General s Report 8 notes that levels of detoxification and follow-on rehabilitation treatment are very low, equating to about 1.25% of those receiving methadone substitution treatment per annum. This scenario is likely to change as goals arising from recent Irish National Drug Strategies now include an increased commitment to opioid dependent patients being directed to eventual drug-free lifestyles and the provision of increased residential detoxification services to facilitate greater levels of rehabilitation. 11,12 Similarly, a major objective of the recently published external review 9 of the Department of Health and Children s Report of Methadone Treatment Services Review Group (1998) was to consider the provisioning of treatments such as detoxification. As relapse is the most common outcome following treatment for a range of psychological and substance use problems moves towards increased opioid detoxification are not without risks related to lapse, overdose and mortality. 18,19 An onus will be placed on treatment centres offering detoxification to assist service users in anticipating and avoiding contexts associated with lapse, a potentially perilous scenario when opioid tolerance is low. As opioid detoxification treatments are likely to increase in Ireland there is a clinical imperative to better understand relapse precipitants in detoxified patients. Factors associated with lapse have been broadly categorised into interoceptive or intrapersonal determinants (mood states or cognitions) and external or interpersonal precipitants (drug availability, drug-related cues and contact with drug using peers). Across all addictions, factors most frequently linked to relapse were found to be negative emotional states, interpersonal conflict and social pressure. 20 According to Donovan 21 the most frequent generic situations associated with relapse include social or peer pressure, a wish for interpersonal inclusion, negative emotional states and an absence of time structure; as well as anger and resentment, normally arising from interpersonal conflict. Early models of relapse 20 were characterised by hierarchical *Kevin Ducray, The Drug Treatment Centre Board, Pearse Street, Dublin 2, Ireland kducray@dtcb.ie Catherine Darker, Department of Public Health and Primary Care, Trinity College, Dublin 2, Ireland *correspondence Bobby P Smyth, The Drug Treatment Centre Board, Pearse Street, Dublin 2, Ireland Department of Public Health and Primary Care, Trinity College, Dublin 2, Ireland 72 Submitted 23rd July 2010 Accepted 2 November 2011

2 classifications of risk factors and a reliance on linear statistical methods. Critiques of earlier static, taxonomic models of relapse, led to the proposal of revised dynamic models. 14, Witkiewitz and Marlatt 24 have noted that the characteristics of alcohol are most amenable to the development of relapse prevention models. Within this research tradition there has been recent interest in incorporating the mechanism by which social variables impact upon the internal (efficacy, expectancies, negative affect, craving, motivation) and behavioural factors (coping and alcohol use) salient to alcohol relapse. 25 These writers have suggested the existence of a dynamic, reciprocal feedback loop between social network and intra-individual factors, noting that social network and interpersonal variables probably moderate alcohol treatment outcomes by impacting upon the co-varying, intra-individual cognitive, affective and behavioural mechanisms of change. Witkiewitz and Marlatt 24 have encouraged scientist-practitioners to incorporate the idiosyncrasies of particular substances such as heroin in the modification and development of drug specific relapse prevention procedures. Focussing specifically on opioid-dependent patients, Bradley et al, 26 identified 11 different factors associated with lapse following inpatient detoxification. Cognitive factors, mood factors and external events were the factors most frequently associated with initial lapse. Social pressure, drug availability and priming rarely contributed to initial lapse. Cognitive, mood and external events as well as withdrawal symptoms were the factors most strongly associated with continued use of opioids following initial lapse. This contrasts with the findings of Marlatt 20 who noted the important role of social pressure as a relapse precipitant for heroin addicts. Social pressure, negative emotional states and interpersonal conflict were found to be the most frequent relapse situation among this cohort. Westermeyer 27 found social factors such as arguments and the loss of supportive relationships to be associated with the probability of relapse. Gossop et al 28 found most lapses to heroin use occurred in the company of other drug users or in social scenarios associated with drug taking. Unnithan, Gossop & Strang, 29 found that drug-related cues and interpersonal events were the most important factors in lapses amongst opioid-dependent individuals. The significance of cues, particularly amongst heroin users, was also noted by Heather, Stallard, and Tebbutt 30 who found temptations or urges in the presence of substance cues were regarded by heroin users to be the most important factor precipitating their last relapse. Maulik, Tripathi and Pal 31 similarly found observing others using and then subsequently wanting to use were the predominant reasons for an initial lapse to heroin use. Westphal, et al 32 conclude that whilst the high-risk situations which may lead to opioid use relapse are too plentiful to list, the empirical literature has indicated interactions with other drug users, exposure to drugs and drug cues and use of other substances are major categories of high-risk situations. There has been a paucity of published research investigating the situational, contextual and psycho-social factors associated with the lapse process following residential detoxification of Irish opioid dependent patients. Little information is known about the potentially modifiable lapse catalysts among this population. A recent study by Smyth et al 33 examining the medium-term outcome of Irish opioid dependent patients admitted for opioid detoxification found that 23% of patients were neither using opiates nor on methadone maintenance when interviewed at follow up months later. Abstinence was significantly associated with completion of the full six-week treatment programme, attendance at aftercare and not having an opioid dependent sibling. A related study 34 which sought to identify factors associated with early relapse found that this process was significantly predicted by general demographic or patient characteristics such as younger age, greater heroin use prior to treatment, history of injecting and a failure to enter aftercare. Those who completed a full six-week inpatient treatment programme also had a significantly delayed relapse. In a 2010 review Veilleux et al 35 argued that physicians and drug abuse treatment facilities must work alongside researchers to better understand the mechanisms that influence treatment retention and develop interventions to overcome barriers to abstinence. As national and international pressure mounts to direct heroin dependent patients towards abstinence based treatments and detoxification from opioids, it will be incumbent upon treatment providers to better understand the opioid relapse trajectory as well as strategies which may prevent this outcome. As noted by Bradley et al 26 by learning how detoxified individuals return to drug use, it may be possible to identify strategies to minimise the risk, impact and scale of this ubiquitous treatment hazard. Our study, by investigating the situational, psychological and social factors implicated in individual lapse processes attempts to further extend the understanding of the more clinically accessible and modifiable determinants of the heroin lapse process following residential treatment within the Irish milieu. This investigation finds its relevance in the scantiness of Irish research on this topic and the anticipated increased shift towards opioid detoxification as a treatment objective. Resultant findings would be of particular salience given the generally unsatisfactory results of abstinence-directed treatments, 13,35 the recent counsel to robustly embed national detoxification efforts in a psycho-social context 9 and the fact that periods following detoxification are associated with an increased risk of death. 36 In light of the danger posed by relapse in the initial perilous period following treatment, enhancing relapse-related coping skills during treatment and aftercare is seen to be vital 13. Given the prospect of increased levels of opioid detoxification treatment in Ireland, the primary aim of the current study was to revisit earlier gathered data to identify factors associated with lapse following discharge from a residential detoxification treatment service among the same cohort of patients previously investigated by Smyth et al elsewhere. 33, Aim As medically supported detoxification from opioids is likely to become an increasingly common treatment activity in Ireland, the aim of this study was to identify and describe the context and factors involved in the opioid lapse trajectory following discharge from an inpatient opioid detoxification programme, thus further extending an understanding of those clinically accessible and therapeutically malleable factors within Irish, and similar, milieus. 3. Method The methods involved in this study are largely described in the related paper by Smyth et al Participants Respondents were recruited from Cuan Dara which is a residential detoxification treatment centre in Dublin. The standard treatment 73

3 episode during this period involved a six-week admission with a medically assisted opioid detoxification taking place during the first two weeks of the admission. The treatment provided during admission is described in more detail elsewhere. 33 Of 144 opioid dependent patients admitted to Cuan Dara with the goal of abstinence, 109 were interviewed months after discharge. Five of the 40 patients not interviewed had died during the intervening period. A further six had relocated. There were twenty individuals still living in Dublin who were not interviewed because they either could not be contacted or because they refused to participate. There was insufficient information available to initiate the interview process with the remaining 11 patients. 3.2 Measures When interviewed, respondents completed the Maudsley Addiction Profile 37 to provide detailed information on patterns of drug use and other relevant behaviours in the month before interview, the findings of which have already been reported. 33 Those patients who had lapsed also completed a modified structured questionnaire, based upon the factors associated with relapse as identified in Bradley et al. s initial qualitative study of opiate users. 26 Whilst this questionnaire was specially developed for this study, reflecting a move from a qualitative to quantitative methodology, no comment regarding the psychometric properties or robustness of this instrument can be presented. The purpose of this structured questionnaire was to fully explore the circumstances of their first lapse to opioid use, as follows. 3.3 Procedures From lapsed respondents information was obtained regarding their location and company when lapse occurred, the type of drug used and method by which the drug was taken. For each potential relapse related factor, participants were asked whether or not this had been relevant to their own lapse. If it was a relevant factor they were asked to categorise it as having either a major or minor role in the lapse episode. Following completion of this list, patients were asked to identify the main factor(s) involved in the lapse, taken from the list presented. 3.4 Data Analysis Descriptive statistics were collated to examine the percentage frequency of factors reported by participants as being pertinent to their relapse. 4. Results The demographic and the other drug use factors reported by the 102 opioid dependent patients who reported a lapse episode following residential detoxification treatment are recorded in Table 1. Sixty six (72%) of respondents who used heroin (either by itself or in combination with methadone) reported being in the company of another drug user during their first lapse. Forty seven (51%) of this group injected during their first lapse and 15 (65%) of the subset of 23 who were alone during heroin re-initiation engaged in this most risky route of drug administration. As shown in Table 2, it emerged that the most important issues involved in the lapse were low mood and difficulties with cravings, with each of these being the main factor in one third of cases, while each had either a major or minor role in three quarters of Table 1. Demographic and drug use factors cited by the 102 opioid dependent patients who reported a lapse episode post residential detoxification treatment. N % Median Admission demographics Median admission age N/A N/A 22 Median period of past opioid use (years) N/A N/A 4 Heroin the main reported opioid used 90 (89) Reporting a history of injecting 82 (80) In a relationship with another opioid user 29 (28) Has an opioid dependent sibling 41 (40) Working at time of admission 4 (4) Male 66 (65) Lapse data Lapsed within one week of discharge 72 (71) Opioid used during first lapse Heroin alone 89 (87) Methadone alone 5 (5) Morphine Sulphate 2 (2) Heroin and Methadone 3 (3) Other combination 2 (2) Unknown 1 (1) Social and other context of first lapse Company when first lapsed Lapsed alone 26 (25) Lapsed with another drug user 72 (71) Unknown social context 4 (4) Lapsed in own home 36 (35) Lapsed in home of another drug user 35 (34) Lapsed under influence of another substance 27 (27) Mood when first lapsed Lapsed when mood worse than usual 65 (64) Lapsed when mood better than usual 26 (26) Lapsed under normal mood 10 (10) Injected on first lapse occasion 50 (49) Injected when alone on first lapse occasion 16 (16) lapse episodes. The next most important factors were ease of access to heroin, due to living with a heroin user for example and missing the support of Cuan Dara, each of these being identified as a major factor by more than 40% of respondents. The factors which had the smallest role in lapse were being under the influence of another substance and knowledge that they could re-access methadone treatment if they became strung out again, these being involved in 16 and 17 cases respectively. A total of 88 (86%) people identified two or more major factors contributing to their lapse. The median number of factors identified as having a major role in the lapse was four (IQR 2 6). Patients rated the quality of their recall regarding the circumstances of the initial lapse as very good in 77% of cases and fairly good in 13% cases, although 10% reported having relatively poor recollection of details. The interviewers rated the patients recall as being very good in 72% of cases and fairly good in 18% of cases. 74

4 Table 2. Factors involved in first lapse following a period of residential detoxification treatment amongst 102 opioid dependent patients Identified as Identified as Identified as the main a major a minor precipitating factor precipitating factor precipitating factor N (%) N (%) N Simply made a decision to start using again 11 (11) 29 (28) 15 Thought that I could just try it once again 8 (8) 40 (39) 16 Mood was bad and wanted a lift 27 (27) 63 (62) 12 Mood was good 3 (3) 16 (16) 11 Wasn t sleeping or felt sick 8 (8) 31 (31) 10 Upset at prospect of meeting partner/family/friends 4 (4) 25 (25) 4 Met someone and offered opioids 9 (9) 37 (37) 4 Missed support of Cuan Dara 9 (9) 43 (43) 14 Ease of access to opioids e.g. living with a user 11 (11) 48 (48) 11 Knew that I could get on a methadone programme if ended up strung out again 1 (1) 13 (13) 4 Under the influence of alcohol or another drug 3 (3) 11 (11) 5 Drug-related cues e.g. saw someone stoned or found works 8 (8) 23 (23) 6 Cravings were too much 30 (30) 63 (62) Discussion Our finding that the majority of lapses occurred during the first week after leaving treatment confirms Gossop et al s findings as to the general alacrity of initial opioid lapse 28, 38 and the notion of a critical period of extraordinarily high-risk immediately after leaving residential treatment during which the best possible support should be provided. Connors et al 39 similarly highlighted the importance of preventing relapse immediately following treatment as the prognosis for ongoing abstinence are significantly better once an initial period of abstinence has been attained. We have discussed issues salient to the rapidity of lapse amongst this patient population in more detail in a related paper. 34 Our findings that half of lapsing heroin users injected on their first lapse occasion and that nearly two-thirds of those who were alone during their first lapse episode injected, reflects scenarios with a high risk potential which need to be proactively addressed when preparing clients for discharge. Such findings underscore the current National Institute for Clinical Excellence (NICE) guideline 36 that it is imperative that detoxification treatments include wider psychosocial support as well as education on post-detoxification vulnerability to relapse and to overdose. Our determination that a large percentage of respondents lapsed in the company of another drug user confirms Gossop et al s 28 observation that most opioid lapses occur in the company or home of other users and emphasises the detrimental role played by certain drug-related peer group influences and social contexts in precipitating opioid use lapses. Having examined social networks and alcohol use disorders, McCrady 40 notes that the impact of social networks on problem drinking may be positive, negative or mixed. Hunter-Reel et al, 25 recognising the impact of social network influences in predicting drinking outcomes, have proposed a model of alcohol relapse in which social variables have a reciprocal influence on drinking outcomes by altering those intraindividual factors and processes salient to alcohol use relapse. Westphal et al 32 have similarly argued the empirical literature indicates encounters with other drug users, exposure to drugs and drug cues (which may imply ease of access) together with the consumption of other drugs are significant categories of high-risk situations and associating with other drug users is a strong predictor of relapse. Social pressure has been found to be the most significant relapse precipitant for heroin addicts. 30 Unnithan et al 29 found interpersonal factors and drug-related cues as being most strongly associated with opioid use lapses. In this study the cited lapse precipitant ease of access is a broad construct that may encapsulate the ready availability of drugs, access to other drug users and exposure to other drug cues. All these risk factors may be amenable to cognitive behavioural interventions. Beck et al 41 argue that as exposure to high-risk situations is inevitable, careful, planned and graded exposure assignments or inoculation to such cues are a clinically sound strategy leading to increased self efficacy. The need to specifically identify the deleterious impact of social interactions; prepare clients for peer or social risk factors; anticipate related intrinsic drug-use cues and their impact on intra-individual functioning under such situations, as well as to harness the potentially beneficial elements of social networks in facilitating desired change is thus strongly recommended as a treatment activity. The factors low mood, cravings, ease of access to opioids, missing the supports offered in treatment, cognitive factors and meeting someone and being offered opiates were similarly ordered in the aforementioned hierarchy of importance, when cited either as the main precipitant to lapse or as a major factor contributing to lapse. More than six times as many respondents reported their mood was worse than usual during first lapse than those who reported lapsing under normal mood. Examining a range of addictive behaviours, Cummings et al 42 found most lapses were associated with factors such as negative emotions, social forces and interpersonal discord. Marlatt 20 found negative emotional states were the intrapersonal factor most highly linked with relapse amongst heroin users and that negative emotional states and interpersonal conflict were associated with a resumption of 75

5 substance use in more than half of such cases. 43 Bradley et al 26 found dysphoric mood states to be the second-most common factor associated with relapse. Negative emotional states have been found to be a pervasive relapse predictor across the majority of studies investigating relapse precipitants. 14 Consistent with the dynamic models 14, discussed earlier, Unnithan et al 29 suggests negative mood states be viewed as a chronic background factor which enhances the risk of relapse when linked with other specific relapse precipitants. Our finding as to the role of negative mood states as a lapse precipitant underscores the importance of clinicians being sensitive to the existence of possible co-morbid depressive disorders, a distal relapse precipitant according to Shiffman s 22 model. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) regards such conditions as being underestimated and under diagnosed and suggest that about 80% of patients with a drug dependency diagnosis also have co-morbid psychiatric diagnoses. They cite European data to highlight the anomaly that whilst co-morbid depression ranges from 5% to 72% and that suicide attempts occur in around 50% of drug dependent patients, treatment teams commonly fail to spot patients with such psychiatric co-morbidity. 44, 45 Craving has been described as the most widely studied yet poorly understood topic in the domain of drug addiction. 46 Niaura 47 argues that whilst the role of craving has been given a position of prominence in many current theories of relapse, debate remains as to the motivational significance of craving in drug-use behaviours. Westphal et al 32 note too the weak empirical relationship between craving and relapse and the contradictory role played by this construct in the area of opioid use. Marlatt and Witkiewitz 48 similarly assert a common finding of contemporary addiction research is the absence of a strong association between craving and relapse. We found that cravings were the most commonly cited main lapse precipitant and together with a mood worse than usual the most commonly cited major factor associated with an opioid lapse. This is of import given Siegel s precipitating factor treatise on cues and cravings. According to his thesis, based upon the Pavlovian conditioning paradigm, the treated addict s experience of cravings are elicited by exposure to exteroceptive (e.g. social settings, the company of friends, paraphernalia) or interoceptive (cognitions, memories, emotions) situations previously paired with drug use. This study s finding as to the significance of cravings as an opioid lapse precipitant confirms the importance of addressing factors associated with this phenomenon early in treatment. 50, 51 A number of writers 25, 40, 48 cite a raft of research to indicate that whilst positive social support is highly predictive of abstinence across a number of addictive behaviours, other social interactions are conversely linked to impeded therapeutic change and an increased risk of relapse. We found missing the support offered by Cuan Dara was ranked fourth, both as the most commonly identified lapse antecedent and the most commonly cited major precipitant. Hunt and Azrin s 52 Community Reinforcement Approach is based on the operant learning principal that substance use is a behaviour determined by arrangements of contingencies and specifically influenced by patterns of reinforcers either lost or received. Working with alcohol use disorders and utilising a social network perspective Hunter-Reel et al 25 have extended reformulated relapse models 14, to describe the interpersonal factors that may interrelate with intrapersonal characteristics and processes to produce change. Given the accepted convention and ubiquitous nature of alcohol consumption in Ireland against the fact heroin users are often a much more marginalised group with multiple morbidities 53 the interplay between inter and intra personal factors within these populations may be dissimilar. Notwithstanding this, our findings confirm the potential salience of social networks in the development of a model reflecting the lapse idiosyncrasies of recently detoxified opioid dependent persons. The above underscores the importance of social interventions which either positively impact upon intrapersonal processes supporting positive change, or reinforce abstinence through interpersonal relationships. A review of social network variables in Alcoholics Anonymous (AA) by Groh et al 54 found not only was support from others in AA to be of great value to recovery but also that individuals with harmful social networks benefited the most from AA involvement. Gossop et al 55 found that predominantly heroin-addicted patients in the UK who regularly attend 12-step groups after residential treatment have been more likely to sustain abstinence from alcohol and opiates. These writers suggest the effectiveness of treatment services may be enhanced by systems that lead to increased involvement and engagement with groups such as Narcotics Anonymous (NA) and AA which have proven to be valuable aftercare resources. Conversely this study s finding that ease of access to drugs, for example living with a user, was the third most influential main risk factor and that 40% of this group had an opioid dependent sibling or intimate partner illustrates the inherent complexities in motivating changes in social networks as a treatment strategy. The synergistic impact of social network influences on intrapersonal variables 28 when living with another opioid user, together with the influence of classically conditioned drug-use or cravings cues 49, 56 in such intimate relationships are likely to produce a blend of post detoxification risk scenarios that are challenging to address. Other factors intermediately ranked as having a major role in a first lapse included thinking one could just try it once again, simply making a decision to start using again, meeting someone and being offered opioids, exposure to cues (e.g. saw someone stoned or found works ) and being upset at the prospect of meeting significant others. Whilst cognitive factors such as simply made a decision to start using again or I thought I could just try it once again were only of moderate importance as main or major relapse precipitants, they were the most frequently cited minor lapse precipitating factors. This finding contrasts with Bradley et al s 26 determination as to the importance of cognitive factors in relapse. According to Beck et al 41 exposure to high-risk triggers activate a chain of cognitive, behavioural and internal experiences potentially culminating in drug-use behaviours. In response to cravings and urges the individual may experience permissive cognitions (e.g. I thought I could just try it once again ) thus activating drug-seeking behaviour. Treatment strategies may include assisting patients in understanding how these transient thoughts about drug use may be elicited by antecedent cues and be proactively managed through cognitive behavioural coping skills. Interventions 41, 50, 51 to manage attractive thoughts about drug use and reduce positive drug expectancies are regarded as a primary active ingredient of cognitive-behavioural treatments 57 and 76

6 are readily available to clinicians preparing patients to cope with such challenges. Consistent with the work of Hunter-Reel 25 many of the other aforementioned factors (e.g. upset at prospect of meeting a significant other, being offered opiates, exposure to drug-related cues such as seeing someone stoned or finding works) are socially or inter-personally mediated, highlighting the adverse impact of certain social network influences on intrapersonal experiences. Our finding as to the relatively small roles played by postdetoxification and discharge symptoms such as sleep difficulties or feeling sick in precipitating opioid lapses are consistent with Bradley et al s 26 verdict that withdrawal symptoms, including sleep difficulties, were not dominant factors associated with relapse. Whilst Unnithan et al 29 noted a high prevalence of symptoms of feeling unwell (either because of withdrawals or because of other health problems) amongst responders, they found no significant difference between opiate lapsers and non-lapsers in terms of either withdrawal symptoms or feeling unwell. Thus residual symptoms of illness or feeling unwell, when experienced after detoxification has been completed and patients have been discharged, may act only as a modest intermediate or contextual background risk factors, compromising abstinence when superimposed with other acute or proximal relapse precipitants. Such findings may provide some consolation to suggestible, alarmist or highly anxious patients and serve as a tool for clinicians wishing to therapeutically normalise the perceived hazard of these physical experiences. That 88 (86%) people in this study identified two or more factors contributing to their lapse and with four being the median number of factors identified as having a major role in the lapse, suggests that the majority of respondents have insight to both the compound nature of their own lapse episodes and an intuitive understanding that multiple interacting risk factors precede and impact upon their lapse. Bradley et al 26 noted relapse factors occur in systemic clusters and argued that a complete model of lapse should encompass the interactions between external events, cognitions and affect in explaining renewed drug use. As has been suggested 14, relapse may thus be best conceptualised as a consequence of a complex nonlinear interaction of background, physiological state, cognitive and coping-skill related factors or similarly as a consequence of the reciprocal dynamic between the individual s social network and their internal cognitive, affective and behavioural processes. 25 Future research examining relationships between these factors should provide exciting data for those seeking to develop a systemic model explaining the relapse process following successful opioid detoxification. Limitations of this study include the reliance on a retrospective assessment of relapse precipitants and the static model of assessment. These features of the methodology bring with them the risks of recall bias and inaccurate identification of true precipitants. 21 The fact that in most instances relapses occurred close to discharge is however likely to have assisted patients in accurate recall. Previous studies report too that drug users are capable of valid self-reports regarding their drug use in environments where social desirability does not play a major role 58 As also noted, whilst retrospective responding has the potential for selectivity in recall, such questioning is often the only practical option given the challenges of engaging relapsing substance abusers under the influence of drugs. 59 The design of the questionnaire based on Bradley et al s 26 work also predated the emergence of more systemic, non-linear and dynamic models of relapse 14, as well as research highlighting the relevance of coping skills in preventing opioid relapse. 60 As the data for this study was gathered more than a decade ago and prior to the development of more dynamic models of relapse, it is thus predisposed towards linear lapse processes and proximal determinants whilst paying less attention to the synergy between these and intermediate, background and distal factors, including the role of social networks. Ideally further research should meet the challenge of both prospectively examining the opioid relapse process and integrating the impact of tonic or underlying background risk factors with clinically relevant phasic proximal factors (such as coping skills, motivation, self efficacy and drug and outcome expectancies) in an effort to develop a systemic and dynamic understanding of the opioid relapse process. Such a focus should include the interaction between environmental, social network and intra-individual factors. On a positive note these findings, taken together with the earlier work of Smyth et al 33, 34 suggest specific areas of focus for those clinicians hoping to support detoxified patients to recognise, anticipate and avoid where possible and better manage clearly identified threats to their newfound drug-free status. The National Institute for Clinical Excellence s guideline on opiate detoxification 36 records that whilst a number of psycho-social treatment models exist, interventions can be unfocussed and both therapist and client may not have a clear understanding of the therapeutic goals of treatment. This body notes too that evidence for adjunctive psychosocial interventions, such as relapse prevention cognitive behavioural therapy is sparse. It is thus hoped this examination of the opioid lapse process, specifically categorising the specific situational and psychosocial hazards recovering patients should anticipate and psychologically prepare for, has contributed to establishing helpful mechanisms of intervention. These findings furthermore neatly interlock with the practical cognitive and behavioural strategies that Wanigaratne et al 61 have argued are fundamental to dealing with relapse triggers. These include recognising high-risk conditions and triggers for craving; developing strategies to minimise exposure to these high-risk situations; learning skills to manage cravings and other distressing emotions without recourse to drug use; learning to control lapses; learning to identify, contest and manage unhelpful or dysfunctional thoughts about drug use; developing emergency plans to manage high-risk situations when other skills are not effective; generating enjoyable sober activities and relationships; constructing a life worth living and attaining a balanced lifestyle. 6. Conclusion In Ireland, as in other jurisdictions, lapse following the inpatient treatment of opioid dependence is typically alacritous. Lapse following detoxification tends to follow key, identifiable high-risk situations, feelings, and cognitions. Identification of these components may be useful for Irish treatment providers facing an increased expectation to provide detoxification-based treatment models and goals. Such findings highlight the need to ensure resources are made available for clinicians to develop and implement contextually relevant treatment strategies which prepare clients to anticipate, interrupt and better manage likely lapse precipitants. 77

7 Acknowledgements: The authors would like to thank Dr. Alan Kelly, Senior Statistician in Bio-Statistics, Department of Public Health & Primary Care, Trinity College Dublin for his advice on statistics. Conflict of interest None. Addendum Since the submission of this paper Prof. J Strang (2011) has published Recovery-oriented drug treatment. An interim report. This National Treatment Agency document, heralding a new direction in UK clinical guidance for treating heroin addicts recommends that clinicians should promote abstinence; helping more heroin users recover and break free of opioid dependence. Professor Strang notes that in focussing more on helping patients overcome their dependence clinicians must guard against relapse and that by drawing upon layered and phased psychosocial and pharmacological approaches this threat, together with associated risks, can be minimised. References 1. Comiskey C, Cox G. ROSIE baseline data report. Dublin: National Advisory Committee on Drugs; Callon C, Wood E, Marsh D, Li K, Montaner J, Kerr T. Barriers and facilitators to methadone maintenance therapy use among illicit opiate injection drug users in Vancouver. J Opioid Manag 2006 Jan-Feb; 2(1): Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998 Apr; 93(4): McKeganey N. The challenge to UK drug policy. Drug-Educ Prev Policy 2007; 14 (6): Hubbard RL, Craddock SG, Anderson J. Overview of 5-year follow up outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 2003 Oct; 25(3): Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, Gossop M. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003 May; 326(7396): Day E. Opiate detoxification in an inpatient setting. London: National Treatment Agency for Substance Misuse, Comptroller Auditor General VFM Report 64. Drug Addiction Treatment & Rehabilitation. Dublin: Office of the Comptroller Auditor General, Farrell M, Barry J. The introduction of the opioid treatment protocol. Dublin: Health Service Executive, Van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry 2006 Sep; 51 (10): National Drugs Strategy : Building on Experience. Dublin: Department of Tourism, Sport and Recreation, National Drugs Strategy (interim) Dublin: Department of Community, Rural and Gaeltacht Affairs, Haug NA, Sorensen JL, Gruber VA, Song JS. Relapse prevention for opioid dependence. In: Marlatt GA, Donovan DM, editors. Relapse Prevention. 2nd ed. New York: Guilford Press; P Witkiewitz K, Marlatt GA. Modeling the complexity of post-treatment drinking: it s a rocky road to relapse. Clin Psychol Rev 2007 Jul; 27(6): Ockene JK, Emmons KM, Mermelstein RJ, Perkins KA, Bonollo DS, Voorhees CC, Hollis JF. Relapse and maintenance issues for smoking cessation. Health Psychol 2000 Jan; 19(1 Suppl): Litman GK, Stapleton J, Oppenheim AN, Peleg M, Jackson P. Situations related to alcoholism relapse. Br J Addict 1983 Dec; 78(4): Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2008 Oct; (4): CD Review. 18. Fugelstad A, Stenbacka M, Leifman A, Nylander M and Thiblin I. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007; 102(3): Naderi-Heiden A, Gleiss A, Bäcker C, Bieber D, Nassan-Agha H, Kasper S, Frey R. Mortality and employment after in-patient opiate detoxification. European Psychiatry: the journal of the Association of European Psychiatrists 2010 July: Marlatt, GA. Relapse Prevention: Theoretical rational and overview of the model. In: Marlatt GA, Gordon JR, editors. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York: Guilford Press; p Donovan, DM. Assessment of addictive behaviors for relapse prevention. In: Donovan DM, Marlatt GA, editors. Assessment of addictive behaviors. New York: Guilford Press; 2005.p Shiffman S. Conceptual issues in the study of relapse. In: Gossop M, editor. Relapse and addictive behaviour. London: Routledge; p Donovan DM. Marlatt's classification of relapse precipitants: is the Emperor still wearing clothes? Addiction 1996 Dec; 91 Suppl: S Witkiewitz K, Marlatt GA. Relapse prevention for alcohol and drug problems: that was Zen, this is Tao. Am Psychol 2004 May-Jun; 59(4): Hunter-Reel D, McCrady B, Hildebrandt T. Emphasizing interpersonal factors: an extension of the Witkiewitz and Marlatt relapse model. Addiction 2009; 104: Bradley BP, Phillips G, Green L, Gossop M. Circumstances surrounding the initial lapse to opiate use following detoxification. Br J Psychiatry 1989 Mar; 154: Westermeyer J. Nontreatment factors affecting treatment outcome in substance abuse. Am J Drug Alcohol Abuse 1989; 15(1): Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry 1989 Mar; 154: Unnithan S, Gossop M, Strang J. Factors associated with relapse among opiate addicts in an out-patient detoxification programme. Br J Psychiatry 1992 Nov; 161: Heather N, Stallard A, Tebbutt J. Importance of substance cues in relapse among 78

8 heroin users: comparison of two methods of investigation. Addict Behav 1991; 16(1-2): Maulik PK, Tripathi BM, Pal HR. Coping behaviors and relapse precipitants in opioid dependence: a study from North India. J Subst Abuse Treat 2002 Apr; 22(3): Westphal J, Wasserman DA, Masson C L, Sorenson JL. Assessment of opioid use. In: Donovan DM, Marlatt GA, editors. Assessment of addictive behaviours. 2nd ed. New York: Guilford; p Smyth BP, Barry J, Lane A, Cotter M, O'Neill M, Quinn C, Keenan E. In-patient treatment of opiate dependence: medium-term follow-up outcomes. Br J Psychiatry 2005 Oct; 187: Smyth BP, Barry J, Keenan E, Ducray K. Lapse and Relapse Following Inpatient Treatment of Opiate Dependence, IMJ 2010 June; 103(6): Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010 Mar; 30(2): National Institute for Clinical Excellence (NICE): Drug Misuse: Opioid detoxification. The NICE guideline. London: National Institute for Health and Clinical Excellence, Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, Edwards C, Strang J. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998 Dec; 93(12): Gossop M, Marsden J, Stewart D, Treacy S. Change and stability of change after treatment of drug misuse: 2-year outcomes from the National Treatment Outcome Research Study (UK). Addict Behav 2002 Mar-Apr; 27(2): Connors G J, Donovan DM, Diclemente C C. Substance Abuse Treatment and the stages of Change: Selecting and Planning Interventions. New York: Guilford Press; McCrady B. S. To have but one true friend: Implications for practice of research on alcohol use disorders and social networks. Psychology of Addictive Behaviors 2004; 18: Beck AT, Wright FD, Newman, CF, Liese BS. Cognitive Therapy of Substance Abuse. New York: Guilford Press; Cummings C, Gordon J R, Marlatt GA. Relapse: Prevention and prediction. In: Miller WR, editor. The addictive behaviours. Oxford: Pergamon Press; p Marlatt GA. Taxonomy of high-risk situations for alcohol relapse: evolution and development of a cognitive-behavioral model. Addiction 1996 Dec; 91 Suppl: S European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Selected issue 3: Co-morbidity in Annual Report 2004: The state of the drugs problem in the European Union and Norway. Luxembourg: Office for Official Publications of the European Communities, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drugs in focus issue 14. Co-morbidity - drug use and mental disorders. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, Drummond DC, Litten RZ, Lowman C, Hunt WA. Craving research: future directions. Addiction 2000 Aug; 95 Suppl 2: S Niaura RS. Cognitive social learning and related perspectives on drug craving. Addiction 2000; 95:S155 S Marlatt G A, Witkiewitz K. Relapse prevention for alcohol and drug problems. In: Marlatt GA, Donovan DM, editors. Relapse prevention: Maintenance strategies in the treatment of addictive behaviors. 2nd ed. New York: Guilford Press; p Siegel, S. Drug Tolerance, Drug Addiction, and Drug Anticipation. Current Directions in Psychological Science 2005 Dec; 14: Kadden R, Carroll K M, Donovan D, Cooney N, Monti P, Abrams D, Litt M, Hester R. Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, Carroll, KM. A Cognitive Behavioural Approach: Treating Cocaine Addiction. Rockville, MD: National Institute on Drug Abuse, Hunt GM, Azrin NH. A community-reinforcement approach to alcoholism. Behav Res Ther 1973 Feb; 11(1): Gossop M. Treating drug misuse problems: evidence of effectiveness. London: National Treatment Agency for Substance Misuse, Groh DR, Jason LA, Keys CB. Social network variables in alcoholics anonymous: a literature review. Clin Psychol Rev 2008 Mar; 28(3): Review. 55. Gossop M, Stewart D, Marsden J. Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: a 5-year follow-up study. Addiction 2008 Jan;103(1): Ludwig AM, Wikler A. "Craving" and relapse to drink. Q J Stud Alcohol 1974 Mar; 35(1): Moos RH. Theory-based active ingredients of effective treatments for substance use disorders. Drug Alcohol Depend 2007 May; 88(2-3): Langendam MW, van Haastrecht HJ, van Ameijden EJ. The validity of drug users' selfreports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities. Int J Epidemiol 1999 Jun; 28(3): Hammerbacher M, Lyvers M. Factors Associated with Relapse among Clients in Australian Substance Disorder Treatment Facilities. Journal of Substance Use :6, Gossop M, Stewart D, Brown N, Marsden J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002; 97: Wanigaratne S, Davis P, Pryce K, Brotchie J. The Effectiveness of Psychological Therapies on Drug-Misusing Clients. London: NTA;

To detox or not to detox: whose choice is it anyway? Dr Ed Day Senior Lecturer in Addiction Psychiatry University of Birmingham

To detox or not to detox: whose choice is it anyway? Dr Ed Day Senior Lecturer in Addiction Psychiatry University of Birmingham To detox or not to detox: whose choice is it anyway? Dr Ed Day Senior Lecturer in Addiction Psychiatry University of Birmingham What do people say they want? Luty J (2004) 104 people attending a community

More information

RELAPSE PRECIPITANTS IN OPIATE ADDICTION : ASSESSMENT IN COMMUNITY TREATMENT SETTING

RELAPSE PRECIPITANTS IN OPIATE ADDICTION : ASSESSMENT IN COMMUNITY TREATMENT SETTING Indian Journal of Psychiatry, 2000, 42 (), 25-257 RELAPSE PRECIPITANTS IN OPIATE ADDICTION : ASSESSMENT IN COMMUNITY TREATMENT SETTING HEM RAJ, R. RAY & BRAHM PRAKASH ABSTRACT Drug and alcohol dependence

More information

The National Community Detoxification Pilot

The National Community Detoxification Pilot The National Community Detoxification Pilot Aoife Dermody, Progression Routes Initiative NDCI, 2011 Community Detoxification Protocols Guidelines for outpatient detoxification from methadone or benzodiazepines

More information

Substance Misuse Treatment Framework (SMTF) Guidance for Evidence Based Psychosocial Interventions in the Treatment of Substance Misuse

Substance Misuse Treatment Framework (SMTF) Guidance for Evidence Based Psychosocial Interventions in the Treatment of Substance Misuse Substance Misuse Treatment Framework (SMTF) Guidance for Evidence Based Psychosocial Interventions in the Treatment of Substance Misuse ISBN 978 0 7504 6272 3 Crown copyright 2011 WG-12567 F9161011 Contents

More information

Effectiveness of Treatment The Evidence

Effectiveness of Treatment The Evidence Effectiveness of Treatment The Evidence The treatment programme at Castle Craig is based on the 12 Step abstinence model. This document describes the evidence for residential and 12 Step treatment programmes.

More information

Special Populations in Alcoholics Anonymous. J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D.

Special Populations in Alcoholics Anonymous. J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D. Special Populations in Alcoholics Anonymous J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D. The vast majority of Alcoholics Anonymous (AA) members in the United States are

More information

Structured intervention in preparing dependent drinkers towards abstinence Windmill Team Alcohol Care Pathway evaluation. May 2014

Structured intervention in preparing dependent drinkers towards abstinence Windmill Team Alcohol Care Pathway evaluation. May 2014 45 Structured intervention in preparing dependent drinkers towards abstinence Windmill Team Alcohol Care Pathway evaluation. May 2014 E. Sharma, A. Smith, K.J. Charge and C. Kouimtsidis Windmill Drug &

More information

PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment

PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment UPDATED 4.6.2015 PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment Psychosocial interventions are structured psychological or social interventions used to address substance-related

More information

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents

More information

Recovery Outcomes for Opiate Users. FRN Research Report November 2013

Recovery Outcomes for Opiate Users. FRN Research Report November 2013 Recovery Outcomes for Opiate Users FRN Research Report November 2013 Introduction Opiate use in America is at epidemic levels. The latest surveys show 4.5 million Americans using prescription painkillers

More information

The efficacy of a relapse prevention programme in the treatment of heroin dependence in China

The efficacy of a relapse prevention programme in the treatment of heroin dependence in China The efficacy of a relapse prevention programme in the treatment of heroin dependence in China Zhao Min 1, Li Xu 1, Wang Zhu-cheng 1, Xu Ding 2, Zhang Yi 2, Zhang Ming-yuang 1 1 Shanghai Mental Health Centre

More information

Audit of the First Twelve months of Cuan Dara Detoxification Unit July 95 to July 96

Audit of the First Twelve months of Cuan Dara Detoxification Unit July 95 to July 96 Audit of the First Twelve months of Cuan Dara Detoxification Unit July 95 to July 96 Authors: Dr. Bobby Smyth, Research Registrar Alison Lane, Staff Nurse EXECUTIVE SUMMARY This audit describes the characteristics

More information

What are the outcomes for assessing drug treatment? A review of long-term observational studies on the treatment of opioid dependence

What are the outcomes for assessing drug treatment? A review of long-term observational studies on the treatment of opioid dependence What are the outcomes for assessing drug treatment? A review of long-term observational studies on the treatment of opioid dependence Lucas Wiessing & Marica Ferri, EMCDDA Background Drug use and addiction,

More information

FRN Research Report August 2011 Patient Outcomes and Relapse Prevention Up to One Year Post- Treatment at La Paloma Treatment Center

FRN Research Report August 2011 Patient Outcomes and Relapse Prevention Up to One Year Post- Treatment at La Paloma Treatment Center Page 1 FRN Research Report August 2011 Patient Outcomes and Relapse Prevention Up to One Year Post- Treatment at La Paloma Treatment Center Background La Paloma Treatment Center offers state-of-the art

More information

Course Description. SEMESTER I Fundamental Concepts of Substance Abuse MODULE OBJECTIVES

Course Description. SEMESTER I Fundamental Concepts of Substance Abuse MODULE OBJECTIVES Course Description SEMESTER I Fundamental Concepts of Substance Abuse MODULE OBJECTIVES At the end of this course participants will be able to: Define and distinguish between substance use, abuse and dependence

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)

More information

POWDER COCAINE: HOW THE TREATMENT SYSTEM IS RESPONDING TO A GROWING PROBLEM

POWDER COCAINE: HOW THE TREATMENT SYSTEM IS RESPONDING TO A GROWING PROBLEM Effective treatment is available for people who have a powder-cocaine problem seven in ten of those who come into treatment either stop using or reduce their use substantially within six months POWDER

More information

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015 The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least

More information

3.1 TWELVE CORE FUNCTIONS OF THE CERTIFIED COUNSELLOR

3.1 TWELVE CORE FUNCTIONS OF THE CERTIFIED COUNSELLOR 3.1 TWELVE CORE FUNCTIONS OF THE CERTIFIED COUNSELLOR The Case Presentation Method is based on the Twelve Core Functions. Scores on the CPM are based on the for each core function. The counsellor must

More information

How To Treat A Drug Addiction

How To Treat A Drug Addiction 1 About drugs Drugs are substances that change a person s physical or mental state. The vast majority of drugs are used to treat medical conditions, both physical and mental. Some, however, are used outside

More information

The story of drug treatment

The story of drug treatment EFFECTIVE TREATMENT CHANGING LIVES www.nta.nhs.uk www.nta.nhs.uk 1 The story of drug treatment The use of illicit drugs is declining in England; more and more people who need help with drug dependency

More information

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA

More information

http://nurse practitioners and physician assistants.advanceweb.com/features/articles/alcohol Abuse.aspx

http://nurse practitioners and physician assistants.advanceweb.com/features/articles/alcohol Abuse.aspx http://nurse practitioners and physician assistants.advanceweb.com/features/articles/alcohol Abuse.aspx Alcohol Abuse By Neva K.Gulsby, PA-C, and Bonnie A. Dadig, EdD, PA-C Posted on: April 18, 2013 Excessive

More information

Addictions. Assessment

Addictions. Assessment Addictions Assessment What is Addiction?..a degree of involvement in a behaviour that can function both to produce pleasure and to provide relief from discomfort, to the point where the costs appear to

More information

LONG-TERM TREATMENT OUTCOME: WHAT ARE THE 11 YEAR OUTCOMES OF TREATMENT FOR HEROIN DEPENDENCE?

LONG-TERM TREATMENT OUTCOME: WHAT ARE THE 11 YEAR OUTCOMES OF TREATMENT FOR HEROIN DEPENDENCE? AUSTRALIAN T R E A T M E N T OU T C O M E STUDY - N S W Funded by the National Health and Medical Research Council and the Australian Government Department of Health. ATOS NSW is a project of the Centre

More information

12 Core Functions. Contact: IBADCC PO Box 1548 Meridian, ID 83680 Ph: 208.468.8802 Fax: 208.466.7693 e-mail: ibadcc@ibadcc.org www.ibadcc.

12 Core Functions. Contact: IBADCC PO Box 1548 Meridian, ID 83680 Ph: 208.468.8802 Fax: 208.466.7693 e-mail: ibadcc@ibadcc.org www.ibadcc. Contact: IBADCC PO Box 1548 Meridian, ID 83680 Ph: 208.468.8802 Fax: 208.466.7693 e-mail: ibadcc@ibadcc.org www.ibadcc.org Page 1 of 9 Twelve Core Functions The Twelve Core Functions of an alcohol/drug

More information

National Addiction Centre, Maudsley Hospital/Institute of Psychiatry, King s College London, London, UK

National Addiction Centre, Maudsley Hospital/Institute of Psychiatry, King s College London, London, UK RESEARCH REPORT doi:10.1111/j.1360-0443.2007.02050.x Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatment

More information

Patients are still addicted Buprenorphine is simply a substitute for heroin or

Patients are still addicted Buprenorphine is simply a substitute for heroin or BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute

More information

PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment

PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment UPDATED 31.5.2016 PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment Psychosocial interventions are structured psychological or social interventions used to address substance-related

More information

FRN Research Report March 2011: Correlation between Patient Relapse and Mental Illness Post-Treatment

FRN Research Report March 2011: Correlation between Patient Relapse and Mental Illness Post-Treatment FRN Research Report March 2011: Correlation between Patient Relapse and Mental Illness Post-Treatment Background Studies show that more than 50% of patients who have been diagnosed with substance abuse

More information

Corl Kerry - Referral and Assessment for Residential Treatment (Tier 4) Introduction Types of Tier 4 Services Services provided at Tier 4

Corl Kerry - Referral and Assessment for Residential Treatment (Tier 4) Introduction Types of Tier 4 Services Services provided at Tier 4 Corl Kerry - Referral and Assessment for Residential Treatment (Tier 4) This document seeks to name the criteria that can guide referrals to residential tier 4 facilities (Part A). It provides guidance

More information

Minnesota Co-occurring Mental Health & Substance Disorders Competencies:

Minnesota Co-occurring Mental Health & Substance Disorders Competencies: Minnesota Co-occurring Mental Health & Substance Disorders Competencies: This document was developed by the Minnesota Department of Human Services over the course of a series of public input meetings held

More information

Treatment of Alcoholism

Treatment of Alcoholism Treatment of Alcoholism Why is it important Prevents further to body by getting people off alcohol. Can prevent death. Helps keep health insurance down. Provides assistance so alcoholics don t t have to

More information

OVERVIEW OF BRIEF INTERVENTION FOR RISKY SUBSTANCE USE IN PRIMARY CARE. Prepared by CASAColumbia

OVERVIEW OF BRIEF INTERVENTION FOR RISKY SUBSTANCE USE IN PRIMARY CARE. Prepared by CASAColumbia OVERVIEW OF BRIEF INTERVENTION FOR RISKY SUBSTANCE USE IN PRIMARY CARE Prepared by CASAColumbia February 2014 Outline Introduction Three Key Steps Engage Motivate Plan Sample Videos 2 INTRODUCTION 3 Addiction

More information

TREATMENT MODALITIES. May, 2013

TREATMENT MODALITIES. May, 2013 TREATMENT MODALITIES May, 2013 Treatment Modalities New York State Office of Alcoholism and Substance Abuse Services (NYS OASAS) regulates the addiction treatment modalities offered in New York State.

More information

EPIDEMIOLOGY OF OPIATE USE

EPIDEMIOLOGY OF OPIATE USE Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months

More information

Topic Area - Dual Diagnosis

Topic Area - Dual Diagnosis Topic Area - Dual Diagnosis Dual Diagnosis is a challenging problem for both mental health and substance misuse services. People with mental health problems, who also suffer from substance misuse are at

More information

drug treatment in england: the road to recovery

drug treatment in england: the road to recovery The use of illegal drugs in England is declining; people who need help to overcome drug dependency are getting it quicker; and more are completing their treatment and recovering drug treatment in ENGlaND:

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call

More information

a five-day medically supervised residential detoxification programme

a five-day medically supervised residential detoxification programme Substance PICU and Acute Misuse and Services Detox Services Psychiatric Cygnet Hospital Intensive Harrogate Care and Acute services a five-day medically supervised residential detoxification programme

More information

The Vermont Legislative Research Shop. Methadone

The Vermont Legislative Research Shop. Methadone The Vermont Legislative Research Shop Methadone Heroin use statistics in Vermont Heroin treatment admissions in Vermont have risen from around 200 patients in 1994 to 833 patients in 2002 (see Figure 1).

More information

Key Considerations in Psychological Interventions for Offenders with Substance Abuse Problems

Key Considerations in Psychological Interventions for Offenders with Substance Abuse Problems Key Considerations in Psychological Interventions for Offenders with Substance Abuse Problems Lu Chan Ching-chuen Senior Clinical Psychologist Charles Pau Wai-ho Clinical Psychologist Correctional Services

More information

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines

More information

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical

More information

Joint Committee on Health and Children

Joint Committee on Health and Children Houses of the Oireachtas Joint Committee on Health and Children A Submission From Homeless & Drugs Services Homeless & Drugs Services September 15 th 2011 1 CONTENTS Page no. 0.1 Introduction 3 0.2 Structure

More information

OVERVIEW WHAT IS POLyDRUG USE? Different examples of polydrug use

OVERVIEW WHAT IS POLyDRUG USE?  Different examples of polydrug use Petrol, paint and other Polydrug inhalants use 237 11 Polydrug use Overview What is polydrug use? Reasons for polydrug use What are the harms of polydrug use? How to assess a person who uses several drugs

More information

UNDERSTANDING CO-OCCURRING DISORDERS. Frances A. Campbell MSN, PMH CNS-BC, CARN Michael Beatty, LCSW, NCGC-1 Bridge To Hope November 18, 2015

UNDERSTANDING CO-OCCURRING DISORDERS. Frances A. Campbell MSN, PMH CNS-BC, CARN Michael Beatty, LCSW, NCGC-1 Bridge To Hope November 18, 2015 UNDERSTANDING CO-OCCURRING DISORDERS Frances A. Campbell MSN, PMH CNS-BC, CARN Michael Beatty, LCSW, NCGC-1 Bridge To Hope November 18, 2015 CO-OCCURRING DISORDERS What does it really mean CO-OCCURRING

More information

DrugFacts: Treatment Approaches for Drug Addiction

DrugFacts: Treatment Approaches for Drug Addiction DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the

More information

Substance Misuse Treatment Framework (SMTF) Guidance for the Provision of Evidence Based Tier 4 Services in the Treatment of Substance Misuse

Substance Misuse Treatment Framework (SMTF) Guidance for the Provision of Evidence Based Tier 4 Services in the Treatment of Substance Misuse Substance Misuse Treatment Framework (SMTF) Guidance for the Provision of Evidence Based Tier 4 Services in the Treatment of Substance Misuse ISBN 978 0 7504 6273 0 Crown copyright 2011 WG-12567 F9161011

More information

Developing the Guernsey treatment system for substance misusers: Phases One and Two. Helen Baldwin Linda Prickett Adam Marr Jim McVeigh

Developing the Guernsey treatment system for substance misusers: Phases One and Two. Helen Baldwin Linda Prickett Adam Marr Jim McVeigh Developing the Guernsey treatment system for substance misusers: Phases One and Two Helen Baldwin Linda Prickett Adam Marr Jim McVeigh Roles and responsibilities of the LJMU research team Helen Baldwin

More information

SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE

SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT OF ALCOHOL MISUSE Date: March 2015 1 1. Introduction Alcohol misuse is a major public health problem in Camden with high rates of hospital

More information

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011 Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids

More information

Wesley Mental Health. Drug and Alcohol Addiction Program. Wesley Hospital Ashfield. Journey together

Wesley Mental Health. Drug and Alcohol Addiction Program. Wesley Hospital Ashfield. Journey together Wesley Mental Health Drug and Alcohol Addiction Program Wesley Hospital Ashfield Journey together Mission Continuing the work of Jesus Christ in Word and deed Wesley Mission is an organisation with a long

More information

Evidence Based Practice in the Treatment of Addiction Treatment of Addiction. Steve Hanson

Evidence Based Practice in the Treatment of Addiction Treatment of Addiction. Steve Hanson Evidence Based Practice in the Treatment of Addiction Treatment of Addiction Steve Hanson History of Addiction Treatment Incarceration Medical Techniques Asylums What We Learned These didn t work Needed

More information

DMRI Drug Misuse Research Initiative

DMRI Drug Misuse Research Initiative DMRI Drug Misuse Research Initiative Executive Summary Dexamphetamine Substitution as a Treatment of Amphetamine Dependence: a Two-Centre Randomised Controlled Trial Final Report submitted to the Department

More information

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,

More information

Dual Diagnosis. Dual Diagnosis Good Practice Guidance, Dept of Health (2002);

Dual Diagnosis. Dual Diagnosis Good Practice Guidance, Dept of Health (2002); Dual Diagnosis Dual Diagnosis is a challenging problem for both mental health and substance misuse services. People with mental health problems, who also suffer from substance misuse are at an increased

More information

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of

More information

PSYCHOSOCIAL INTERVENTIONS FOR SUBSTANCE MISUSE. From Academic Efficacy to Real World Treatment

PSYCHOSOCIAL INTERVENTIONS FOR SUBSTANCE MISUSE. From Academic Efficacy to Real World Treatment PSYCHOSOCIAL INTERVENTIONS FOR SUBSTANCE MISUSE From Academic Efficacy to Real World Treatment Pompidou Treatment Platform Cyprus May 09 Brion Sweeney Clinical Director: Substance Misuse Services HSE Greater

More information

MOVING TOWARD EVIDENCE-BASED PRACTICE FOR ADDICTION TREATMENT

MOVING TOWARD EVIDENCE-BASED PRACTICE FOR ADDICTION TREATMENT MOVING TOWARD EVIDENCE-BASED PRACTICE FOR ADDICTION TREATMENT June, 2014 Dean L. Babcock, LCAC, LCSW Associate Vice President Eskenazi Health Midtown Community Mental Health Centers Why is Evidence-Based

More information

NETWORK THERAPY: Using Family and Peer Support To Improve Your Treatment Outcome

NETWORK THERAPY: Using Family and Peer Support To Improve Your Treatment Outcome NETWORK THERAPY: Using Family and Peer Support To Improve Your Treatment Outcome Marc Galanter, M.D. Director, Division of Alcoholism and Drug Abuse Professor of Psychiatry New York University Medical

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SPECIAL HEALTH AUTHORITY TENTH WAVE WORK PROGRAMME DRUG MISUSE. Psychosocial interventions in drug misuse

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SPECIAL HEALTH AUTHORITY TENTH WAVE WORK PROGRAMME DRUG MISUSE. Psychosocial interventions in drug misuse Attachment B NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SPECIAL HEALTH AUTHORITY TENTH WAVE WORK PROGRAMME DRUG MISUSE Psychosocial interventions in drug misuse On 16 th June 2004 the Department of Health

More information

Opiate Abuse and Mental Illness

Opiate Abuse and Mental Illness visited on Page 1 of 5 LEARN MORE (HTTP://WWW.NAMI.ORG/LEARN-MORE) FIND SUPPORT (HTTP://WWW.NAMI.ORG/FIND-SUPPORT) GET INVOLVED (HTTP://WWW.NAMI.ORG/GET-INVOLVED) DONATE (HTTPS://NAMI360.NAMI.ORG/EWEB/DYNAMICPAGE.ASPX?

More information

Substance misuse and behavioural addictions

Substance misuse and behavioural addictions Substance misuse and behavioural addictions Information about our services for primary healthcare professionals PROVIDING QUALITY INSPIRING INNOVATION DELIVERING VALUE Our substance misuse and behavioural

More information

Michael Brennan, MA, LMHC Providence St. Peter Hospital Crisis Services

Michael Brennan, MA, LMHC Providence St. Peter Hospital Crisis Services Michael Brennan, MA, LMHC Providence St. Peter Hospital Crisis Services Welcome to the E.R.: Emergency: noun Webster 1. a sudden, urgent, usually unexpected occurrence or occasion requiring immediate action.

More information

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15 ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;/13;06/14;07/15 WRITTEN BY Jim Johnson Page 1 REVISED BY AUTHORIZED BY Jessica Moeller Debra Johnson I. APPLICATION: THUMB

More information

THE STORY OF DRUG TREATMENT

THE STORY OF DRUG TREATMENT THE STORY OF DRUG TREATMENT EFFECTIVE TREATMENT CHANGING LIVES The story of drug treatment The goal of all treatment is for drug users to achieve abstinence from their drug or drugs of dependency. For

More information

Opioid Addiction Treatment. Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine

Opioid Addiction Treatment. Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine Opioid Addiction Treatment Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine 1 Continuity of Care: A Critical Goal Is shorter cheaper? Re-hospitalization in 296 dependent patients

More information

YOUNG ADULTS IN DUAL DIAGNOSIS TREATMENT: COMPARISON TO OLDER ADULTS AT INTAKE AND POST-TREATMENT

YOUNG ADULTS IN DUAL DIAGNOSIS TREATMENT: COMPARISON TO OLDER ADULTS AT INTAKE AND POST-TREATMENT YOUNG ADULTS IN DUAL DIAGNOSIS TREATMENT: COMPARISON TO OLDER ADULTS AT INTAKE AND POST-TREATMENT Siobhan A. Morse, MHSA, CRC, CAI, MAC Director of Fidelity and Research Foundations Recovery Network YOUNG

More information

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System. New Jersey Substance Abuse Monitoring System The NJSAMS Report May 2011 Admissions to Substance Abuse Treatment in New Jersey eroin is a semi-synthetic opioid drug derived from morphine. It has a high

More information

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol. Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.

More information

H-SOAP STUDY. Hospital-based Services for Opioid- and Alcohol-addicted Patients

H-SOAP STUDY. Hospital-based Services for Opioid- and Alcohol-addicted Patients H-SOAP STUDY Hospital-based Services for Opioid- and Alcohol-addicted Patients Meldon Kahan, Anita Srivastava, Kate Hardy, Sarah Clarke Canadian Society of Addiction Medicine 2014 October 17, 2014 1 Few

More information

Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances

Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances page 1/5 Scientific Facts on Psychoactive Drugs Tobacco, Alcohol, and Illicit Substances Source document: WHO (2004) Summary & Details: GreenFacts Context - Psychoactive drugs such as tobacco, alcohol,

More information

Opiate Addiction, Pharmacological Treatment Approaches CO-OCCURRING MENTAL HEALTH DISORDERS JOSEPH A. BEBO MA, CAGS, LADC1

Opiate Addiction, Pharmacological Treatment Approaches CO-OCCURRING MENTAL HEALTH DISORDERS JOSEPH A. BEBO MA, CAGS, LADC1 Opiate Addiction, Pharmacological Treatment Approaches CO-OCCURRING MENTAL HEALTH DISORDERS JOSEPH A. BEBO MA, CAGS, LADC1 Disclosure Statement Prevalence of Opioid Addiction 100 Individuals Die Every

More information

Overview of the Breaking Free research and evaluation programme. Based on the MRC framework for developing and evaluating complex interventions

Overview of the Breaking Free research and evaluation programme. Based on the MRC framework for developing and evaluating complex interventions Overview of the Breaking Free research and evaluation programme Based on the MRC framework for developing and evaluating complex interventions June 2015 1 Overview of the Breaking Free research and evaluation

More information

Addiction is a Brain Disease

Addiction is a Brain Disease Addiction is a Brain Disease By ALAN I. LESHNER, MD A core concept evolving with scientific advances over the past decade is that drug addiction is a brain disease that develops over time as a result of

More information

ORGANIZATION OF AMERICAN STATES

ORGANIZATION OF AMERICAN STATES ORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION FIRST INTER-REGIONAL FORUM OF EU-LAC CITIES: PUBLIC POLICIES IN DRUG TREATMENT April 2 5, 2008 Santo Domingo, Dominican Republic

More information

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment

More information

Protocol for Accessing Residential Detoxification & Rehabilitation

Protocol for Accessing Residential Detoxification & Rehabilitation Protocol for Accessing Residential Detoxification & Rehabilitation Protocol - working group members: Julie Murray, Alcohol & Drugs Partnership Co-ordinator Lynda Mays, Clinical Services Manager, Addictions,

More information

California Society of Addiction Medicine (CSAM) Consumer Q&As

California Society of Addiction Medicine (CSAM) Consumer Q&As C o n s u m e r Q & A 1 California Society of Addiction Medicine (CSAM) Consumer Q&As Q: Is addiction a disease? A: Addiction is a chronic disorder, like heart disease or diabetes. A chronic disorder is

More information

Tolerance and Dependence

Tolerance and Dependence Tolerance and Dependence Drug Tolerance is a decrease in the effect of a drug as a consequence of repeated exposure. Change over repeated exposures. Different effects may show different tolerance. Tolerance

More information

Alcohol Dependence and Motivational Interviewing

Alcohol Dependence and Motivational Interviewing Alcohol Dependence and Motivational Interviewing Assessment of Alcohol Misuse Checklist Establish rapport patients are often resistant Longitudinal history of alcohol use Assess additional drug use Establish

More information

Non medical use of prescription medicines existing WHO advice

Non medical use of prescription medicines existing WHO advice Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations

More information

Ross McCormick is the director of the Goodfellow Unit, University of Auckland. Key points

Ross McCormick is the director of the Goodfellow Unit, University of Auckland. Key points 1 of 5 Focus Treating drug addiction in general practice Ross McCormick is the director of the Goodfellow Unit, University of Auckland Introduction Today s drug seeking list according to the Ministry of

More information

What is Addiction? DSM-IV-TR Substance Abuse Criteria

What is Addiction? DSM-IV-TR Substance Abuse Criteria Module 2: Understanding Addiction, Recovery, and Recovery Oriented Systems of Care This module reviews the processes involved in addiction and what is involved in recovering an addiction free lifestyle.

More information

How To Know If You Can Get Help For An Addiction

How To Know If You Can Get Help For An Addiction 2014 FLORIDA SUBSTANCE ABUSE LEVEL OF CARE CLINICAL CRITERIA SUBSTANCE ABUSE LEVEL OF CARE CLINICAL CRITERIA Overview Psychcare strives to provide quality care in the least restrictive environment. An

More information

Health Care Service System in Thailand for Patients with Alcohol Use Disorder

Health Care Service System in Thailand for Patients with Alcohol Use Disorder Health Care Service System in Thailand for Patients with Alcohol Use Disorder Health Care Service System In Thailand Screening for alcohol use disorder and withdrawal syndrome AUDIT MAST CAGE CIWA or AWS

More information

Martha Brewer, MS, LPC,LADC. Substance Abuse and Treatment

Martha Brewer, MS, LPC,LADC. Substance Abuse and Treatment Martha Brewer, MS, LPC,LADC Substance Abuse and Treatment What is a substance use disorder? Long-term and chronic illness Can affect anyone: rich or poor, male or female, employed or unemployed, young

More information

These changes are prominent in individuals with severe disorders, but also occur at the mild or moderate level.

These changes are prominent in individuals with severe disorders, but also occur at the mild or moderate level. Substance-Related Disorders DSM-V Many people use words like alcoholism, drug dependence and addiction as general descriptive terms without a clear understanding of their meaning. What does it really mean

More information

Clinical Criteria 4.201 Inpatient Medical Withdrawal Management 4.201 Substance Use Inpatient Withdrawal Management (Adults and Adolescents)

Clinical Criteria 4.201 Inpatient Medical Withdrawal Management 4.201 Substance Use Inpatient Withdrawal Management (Adults and Adolescents) 4.201 Inpatient Medical Withdrawal Management 4.201 Substance Use Inpatient Withdrawal Management (Adults and Adolescents) Description of Services: Inpatient withdrawal management is comprised of services

More information

Dual Diagnosis: Models of Care and Local Pathways AGENDA. Part one: Part two:

Dual Diagnosis: Models of Care and Local Pathways AGENDA. Part one: Part two: Slide 1 Dual Diagnosis: Models of Care and Local Pathways St. Anne s Community Services Dual Diagnosis Project Slide 2 AGENDA Part one: Models of Care. Clinical Guidelines & Evidence Base Local Care Pathways

More information

Abstinence and drug abuse treatment: Results from the Drug Outcome Research in Scotland study

Abstinence and drug abuse treatment: Results from the Drug Outcome Research in Scotland study Drugs: education, prevention and policy, December 2006; 13(6): 537 550 Abstinence and drug abuse treatment: Results from the Drug Outcome Research in Scotland study NEIL MCKEGANEY 1, MICHAEL BLOOR 1, MICHELE

More information

Procedure/ Revenue Code. Billing NPI Required. Rendering NPI Required. Service/Revenue Code Description. Yes No No

Procedure/ Revenue Code. Billing NPI Required. Rendering NPI Required. Service/Revenue Code Description. Yes No No Procedure/ Revenue Code Service/Revenue Code Description Billing NPI Rendering NPI Attending/ Admitting NPI 0100 Inpatient Services Yes No Yes 0114 Room & Board - private psychiatric Yes No Yes 0124 Room

More information

Antidepressant Skills @ Work Dealing with Mood Problems in the Workplace

Antidepressant Skills @ Work Dealing with Mood Problems in the Workplace Antidepressant Skills @ Work Dealing with Mood Problems in the Workplace Dr. Joti Samra PhD, R.Psych. Adjunct Professor & Research Scientist CARMHA www.carmha.ca Dr. Merv Gilbert PhD, R.Psych. Principal

More information

BUILDING RECOVERY IN COMMUNITIES www.nta.nhs.uk

BUILDING RECOVERY IN COMMUNITIES www.nta.nhs.uk Parents with drug problems present real risks to their children. But drug treatment helps them to overcome their addiction and look after their children better PARENTS WITH DRUG PROBLEMS: HOW TREATMENT

More information

Submission to Department of Public Expenditure and Reform on comprehensive review of public expenditure

Submission to Department of Public Expenditure and Reform on comprehensive review of public expenditure Submission to Department of Public Expenditure and Reform on comprehensive review of public expenditure An introduction to reducing costs and improving clinical outcomes for people with addiction issues.

More information

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification

More information

Alcohol Addiction. Introduction. Overview and Facts. Symptoms

Alcohol Addiction. Introduction. Overview and Facts. Symptoms Alcohol Addiction Alcohol Addiction Introduction Alcohol is a drug. It is classed as a depressant, meaning that it slows down vital functions -resulting in slurred speech, unsteady movement, disturbed

More information

Discontinuation: Involuntary Discharge

Discontinuation: Involuntary Discharge Discontinuation: Involuntary Discharge TYPICALLY A PROCESS NOT AN EVENT Objectives 2 Review indications for discharge. Develop a therapeutic approach, in the context of the nature of Substance Use Disorders.

More information